An Australian stem cell and regenerative medicine company

April 03, 2020

Cynata Therapeutics (ASX:CYP) 1H20 results & outlook

View Report

Finance News Network discusses with Cynata CEO Dr Ross Macdonald the Company’s 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform

Read More

January 16, 2020

Shaw and Partners Flashnote: “UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia; ‘Buy’ Rating; Price Target $3.00”

View Report

View the latest Shaw and Partners Research Update for Cynata Therapeutics



December 17, 2019

H.C. Wainwright & Co. Company Update: “Preclinical Sepsis Data Hint at Therapeutic Potential; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics

December 10, 2019

Shaw and Partners Flash Note: “Positive News Flow Continues to Support Outlook; ‘Buy’ Rating; Price Target $3.00”

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

October 18, 2019

Shaw and Partners Flash Note: “Cynata and Sumitomo Withdraw from Acquisition Discussions; ‘Buy’ Rating; Price Target $3.00

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics